CLINICAL TRIALS PROFILE FOR TIMOLOL

505(b)(2) Clinical Trials for timolol

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT01426113 ↗	A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma	Terminated	Allergan	Phase 3	2011-09-01	The purpose of this study is to assess the safety and efficacy of a new formulation of bimatoprost ophthalmic solution compared to timolol ophthalmic solution in the treatment of paediatric patients with glaucoma.
New Formulation	NCT02973880 ↗	Clinical Study to Evaluate the Efficacy and Tolerability of an Anti-inflammatory/Antibiotic Treatment Following Ocular Cataract Extraction	Completed	Sintesi Research Srl	Phase 3	2017-10-15	Cataract is an ophthalmic disease that usually affects the elderly population. Cataract surgery with phaco-emulsification is now the most frequently performed intraocular surgical procedure in the developed world. However, differences in surgical technique impact the severity of surgical trauma and post-operative recovery. The amount of post-operative ocular pain and inflammation plays a significant role in the Patient's perception of the surgical success. Several ophthalmic products have been studied in the management of post-surgery ocular inflammation and pain following cataract surgery. Corticosteroids are considered the gold standard for the treatment of ocular inflammation, and their most commonly used route of administration is the topical instillation as eye drops formulation. After topical administration of Dexamethasone, the concentration in the anterior chamber increases and declines within hours, necessitating frequent daily instillations of eye drops for several weeks. This might be associated with compliance issues, particularly in elderly Patients or in individuals with disabilities. A pharmaceutical formulation allowing for a less frequent administration could therefore be an attractive alternative. NETILDEX™ eye drops solution, containing Netilmicin Sulfate 4.55 mg (3mg/ml) and Dexamethasone Disodium Phosphate 1.32 mg (1mg/ml), is already available for Patients. A new ophthalmic gel, preservative-free formulation has been developed. This new formulation has been tested in pre-clinical animal studies and in a clinical trial. The new formulation contains Xanthan gum, a high molecular mass polysaccharide approved by the FDA in 1969 for food products. It is used in the product as viscosity enhancer and to give to the product pseudo-plastic characteristics and prolonged ocular retention time. The purpose of this trial is to show that the administration of a reduced dose of NETILDEX ™ gel 2 times a day starting on the day of cataract extraction by means of phaco-emulsification and administered until 14 days after surgery is sufficient to obtain a non-inferior efficacy of the NETILDEX ™ eye drops solution administered 4 times a day for the same period.
New Formulation	NCT02973880 ↗	Clinical Study to Evaluate the Efficacy and Tolerability of an Anti-inflammatory/Antibiotic Treatment Following Ocular Cataract Extraction	Completed	SIFI SpA	Phase 3	2017-10-15	Cataract is an ophthalmic disease that usually affects the elderly population. Cataract surgery with phaco-emulsification is now the most frequently performed intraocular surgical procedure in the developed world. However, differences in surgical technique impact the severity of surgical trauma and post-operative recovery. The amount of post-operative ocular pain and inflammation plays a significant role in the Patient's perception of the surgical success. Several ophthalmic products have been studied in the management of post-surgery ocular inflammation and pain following cataract surgery. Corticosteroids are considered the gold standard for the treatment of ocular inflammation, and their most commonly used route of administration is the topical instillation as eye drops formulation. After topical administration of Dexamethasone, the concentration in the anterior chamber increases and declines within hours, necessitating frequent daily instillations of eye drops for several weeks. This might be associated with compliance issues, particularly in elderly Patients or in individuals with disabilities. A pharmaceutical formulation allowing for a less frequent administration could therefore be an attractive alternative. NETILDEX™ eye drops solution, containing Netilmicin Sulfate 4.55 mg (3mg/ml) and Dexamethasone Disodium Phosphate 1.32 mg (1mg/ml), is already available for Patients. A new ophthalmic gel, preservative-free formulation has been developed. This new formulation has been tested in pre-clinical animal studies and in a clinical trial. The new formulation contains Xanthan gum, a high molecular mass polysaccharide approved by the FDA in 1969 for food products. It is used in the product as viscosity enhancer and to give to the product pseudo-plastic characteristics and prolonged ocular retention time. The purpose of this trial is to show that the administration of a reduced dose of NETILDEX ™ gel 2 times a day starting on the day of cataract extraction by means of phaco-emulsification and administered until 14 days after surgery is sufficient to obtain a non-inferior efficacy of the NETILDEX ™ eye drops solution administered 4 times a day for the same period.
New Formulation	NCT05857267 ↗	Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety	Recruiting	Laboratorios Poen	Phase 4	2023-03-07	The goal of this study is to evaluate the tolerability of the new formulation of Dorzolamide+Timolol preservative free developed in OSD Aptar Pharma multidose system in comparison with Dorzolamide +Timolol BAK preserved ophthalmic formulation.

All Clinical Trials for timolol

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004641 ↗	Prevention of Esophageal Varices by Beta-Adrenergic Blockers	Completed	Yale University	Phase 3	1993-08-01	The purpose of this study is to learn whether timolol is useful in preventing or delaying the appearance of gastroesophageal varices, a complication that may develop in the future as a consequence of liver disease. Cirrhosis causes an increased resistance of blood flowing through the liver. This leads to an increased pressure in the portal vein (the vein that takes blood to your liver). High portal pressure is responsible for the appearance of complications of chronic liver disease such as varices and variceal bleeding (bleeding from veins in your esophagus). Timolol belongs to a group of medications called beta-blockers. Beta-blockers decrease high portal pressure and previous studies have shown that beta-blocker pills are useful in preventing bleeding from varices in patients who already have varices. A more desirable effect would be if these pills could prevent not only bleeding from varices but the appearance of varices (and therefore of bleeding).
NCT00004641 ↗	Prevention of Esophageal Varices by Beta-Adrenergic Blockers	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 3	1993-08-01	The purpose of this study is to learn whether timolol is useful in preventing or delaying the appearance of gastroesophageal varices, a complication that may develop in the future as a consequence of liver disease. Cirrhosis causes an increased resistance of blood flowing through the liver. This leads to an increased pressure in the portal vein (the vein that takes blood to your liver). High portal pressure is responsible for the appearance of complications of chronic liver disease such as varices and variceal bleeding (bleeding from veins in your esophagus). Timolol belongs to a group of medications called beta-blockers. Beta-blockers decrease high portal pressure and previous studies have shown that beta-blocker pills are useful in preventing bleeding from varices in patients who already have varices. A more desirable effect would be if these pills could prevent not only bleeding from varices but the appearance of varices (and therefore of bleeding).
NCT00006398 ↗	Prevention of Esophageal Varices by Beta-Adrenergic Blockers	Completed	Yale University	Phase 3	1993-08-01	The purpose of this study is to learn whether timolol is useful in preventing or delaying the appearance of gastroesophageal varices, a complication that may develop in the future as a consequence of liver disease. Cirrhosis causes an increased resistance of blood flowing through the liver. This leads to an increased pressure in the portal vein (the vein that takes blood to your liver). High portal pressure is responsible for the appearance of complications of chronic liver disease such as varices and variceal bleeding (bleeding from veins in your esophagus). Timolol belongs to a group of medications called beta-blockers. Beta-blockers decrease high portal pressure and previous studies have shown that beta-blocker pills are useful in preventing bleeding from varices in patients who already have varices. A more desirable effect would be if these pills could prevent not only bleeding from varices but the appearance of varices (and therefore of bleeding).
NCT00006398 ↗	Prevention of Esophageal Varices by Beta-Adrenergic Blockers	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 3	1993-08-01	The purpose of this study is to learn whether timolol is useful in preventing or delaying the appearance of gastroesophageal varices, a complication that may develop in the future as a consequence of liver disease. Cirrhosis causes an increased resistance of blood flowing through the liver. This leads to an increased pressure in the portal vein (the vein that takes blood to your liver). High portal pressure is responsible for the appearance of complications of chronic liver disease such as varices and variceal bleeding (bleeding from veins in your esophagus). Timolol belongs to a group of medications called beta-blockers. Beta-blockers decrease high portal pressure and previous studies have shown that beta-blocker pills are useful in preventing bleeding from varices in patients who already have varices. A more desirable effect would be if these pills could prevent not only bleeding from varices but the appearance of varices (and therefore of bleeding).
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	US Department of Veterans Affairs		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	VA Office of Research and Development		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00061542 ↗	Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension	Completed	Alcon Research	Phase 3	2003-01-01	The purpose of this study is to evaluate the safety and efficacy of BETOPTIC S and Timolol Gel-forming solution in pediatric patients. Patients will dose with study drug at 8 am and 8 pm daily for twelve weeks. Patients will have vision tested, slit lamp exam, blood pressure and pulse checks at each visit. Patients will have a dilated fundus exam and corneal measurements taken at first and last visit.

Clinical Trial Conditions for timolol

Condition Name

Condition Name for timolol
Intervention	Trials
Ocular Hypertension	122
Glaucoma	77
Open-angle Glaucoma	39
Glaucoma, Open-Angle	21

Condition MeSH

Condition MeSH for timolol
Intervention	Trials
Glaucoma	179
Ocular Hypertension	140
Hypertension	118
Glaucoma, Open-Angle	116

Clinical Trial Locations for timolol

Trials by Country

Trials by Country for timolol
Location	Trials
United States	390
China	31
Italy	24
Germany	22
Canada	21

Trials by US State

Trials by US State for timolol
Location	Trials
California	33
Texas	29
New York	19
Pennsylvania	19
Georgia	18

Clinical Trial Progress for timolol

Clinical Trial Phase

Clinical Trial Phase for timolol
Clinical Trial Phase	Trials
PHASE4	2
PHASE3	3
PHASE2	3

Clinical Trial Status

Clinical Trial Status for timolol
Clinical Trial Phase	Trials
Completed	173
RECRUITING	28
Terminated	16

Clinical Trial Sponsors for timolol

Sponsor Name

Sponsor Name for timolol
Sponsor	Trials
Alcon Research	37
Allergan	35
Pfizer	15

Sponsor Type

Sponsor Type for timolol
Sponsor	Trials
Industry	183
Other	124
NIH	5

Timolol: Clinical Trials, Market Dynamics, and Future Outlook

Last updated: February 19, 2026

This report analyzes the current landscape of Timolol, focusing on its clinical trial status, market performance, and projected trajectory. Timolol, a non-selective beta-adrenergic receptor antagonist, has a well-established history in treating cardiovascular conditions and glaucoma. Recent developments in clinical trials and evolving market dynamics necessitate a focused examination for R&D and investment strategy.

What is Timolol's Current Clinical Trial Status?

Timolol is a mature drug with an extensive history of regulatory approval and widespread clinical use. The majority of its therapeutic applications are supported by decades of research and clinical experience. New clinical trials for Timolol are primarily focused on exploring novel delivery methods, combination therapies, or specific patient subpopulations where its efficacy might be re-evaluated or enhanced.

Key Areas of Ongoing or Recent Clinical Interest:

• Ophthalmic Formulations: Research continues on developing improved or sustained-release formulations of Timolol for glaucoma management to enhance patient compliance and reduce the frequency of dosing. This includes exploring microparticle or implantable systems.
• Combination Therapies for Glaucoma: Trials investigate the synergistic effects of Timolol in combination with other ocular hypotensive agents (e.g., prostaglandin analogs, alpha-adrenergic agonists) to achieve lower intraocular pressures (IOP) in patients who do not respond adequately to monotherapy.
• Cardiovascular Applications: While primary cardiovascular indications are well-defined, some research may explore Timolol in specific perioperative settings or in conjunction with newer cardiovascular agents, though this is less common for new molecule development and more about optimizing existing use.
• Rare or Orphan Diseases: In limited instances, Timolol may be investigated for off-label uses or in rare conditions where its pharmacodynamic profile could offer a therapeutic benefit, often through academic research or small investigator-initiated studies.

Notable Clinical Trial Registries:

• ClinicalTrials.gov: As of [Current Month, Current Year], a search for "Timolol" yields [Number] results, ranging from early-phase studies to observational analyses and post-marketing surveillance. The majority of these are focused on ophthalmology.
• European Union Clinical Trials Register (EU CTR): Similar to ClinicalTrials.gov, the EU CTR will list registered trials within the European Economic Area. The focus remains largely on ophthalmic applications.

Recent Approvals and Label Expansions:

Timolol has not experienced significant label expansions or novel drug approvals in recent years. Its established therapeutic profile means that regulatory focus is typically on post-market surveillance and ensuring the safety and efficacy of existing indications. Generic formulations of Timolol eye drops and oral tablets remain widely available and prescribed.

How is Timolol Performing in the Market?

Timolol's market presence is characterized by its maturity, widespread availability of generic versions, and established therapeutic niches. Its market share is significantly influenced by the prevalence of its target conditions and competition from newer, often more specialized, therapeutic agents.

Market Segmentation:

• Ophthalmology: This is the dominant market segment for Timolol. It remains a first-line or second-line treatment for open-angle glaucoma and ocular hypertension due to its cost-effectiveness and efficacy in reducing IOP.
  • Key Competitors: Prostaglandin analogs (e.g., latanoprost, bimatoprost), carbonic anhydrase inhibitors (e.g., dorzolamide), alpha-adrenergic agonists (e.g., brimonidine), and other beta-blockers (e.g., betaxolol). Fixed-combination eye drops are also significant competitors.
  • Market Share Impact: The widespread availability of generic Timolol ophthalmic solutions contributes to a substantial volume, but revenue is constrained by low pricing.
• Cardiology: Timolol was historically used for conditions like hypertension and angina. However, newer classes of antihypertensives (e.g., ACE inhibitors, ARBs, calcium channel blockers, newer beta-blockers with cardioselectivity) have largely superseded it for these indications due to better tolerability profiles and more targeted mechanisms.
  • Niche Use: Its use in cardiology is now limited to specific scenarios, such as post-myocardial infarction or in patients where other agents are contraindicated or ineffective.
  • Market Share Impact: The cardiology market segment for Timolol is significantly smaller than ophthalmology and is generally declining as newer agents gain preference.

Market Size and Growth Projections:

Quantifying the precise global market size for Timolol is challenging due to the fragmented nature of generic drug sales and the difficulty in isolating its market share from broader therapeutic class estimates. However, industry analyses indicate:

• Global Glaucoma Market: The global glaucoma market is projected to grow from approximately USD [Value] billion in [Year] to USD [Value] billion by [Year], driven by an aging population and increasing disease prevalence. Timolol, as a foundational therapy, will continue to capture a portion of this market, but its growth will be tempered by pricing pressures and the rise of premium-priced novel therapies.
• Cardiology Market: The broader cardiovascular drug market is vast but Timolol's share within it is minimal and likely stagnant or declining.

Factors Influencing Market Performance:

• Generic Competition: The primary driver of Timolol's market performance is its status as a widely available generic medication. This leads to significant price erosion, making volume the key driver of revenue.
• Cost-Effectiveness: For payers and healthcare systems, Timolol offers a highly cost-effective solution for managing glaucoma, ensuring its continued prescription.
• Established Safety Profile: Decades of use have resulted in a well-understood safety and efficacy profile, which fosters physician confidence.
• Competition from Newer Agents: In both ophthalmology and cardiology, newer drugs with improved efficacy, tolerability, or convenience (e.g., once-daily dosing, fewer side effects) pose a continuous competitive threat.
• Aging Population: The increasing global prevalence of age-related conditions like glaucoma directly contributes to the sustained demand for treatments like Timolol.
• Regulatory Landscape: Favorable regulatory pathways for generic drugs ensure continued market access.

Pricing Trends:

• Ophthalmic Solutions: Generic Timolol ophthalmic solutions typically range from [Price Range] per bottle, depending on concentration and unit volume. Prices are highly competitive.
• Oral Tablets: Generic Timolol oral tablets for cardiovascular indications are also priced competitively, typically in the [Price Range] per month range.

What is the Future Outlook for Timolol?

The future outlook for Timolol is one of sustained, albeit modest, relevance, primarily driven by its established role in ophthalmology. It is unlikely to see a resurgence in major new therapeutic indications but will continue to serve as a foundational treatment option.

Projected Trajectory:

• Ophthalmology Dominance: Timolol will remain a cornerstone therapy for open-angle glaucoma and ocular hypertension. Its cost-effectiveness and proven efficacy will ensure its place in treatment algorithms, especially in resource-constrained settings and for patients requiring dual therapy. The market will likely see continued introduction of fixed-combination products that include Timolol, albeit with declining individual market share contribution for the Timolol component.
• Declining Cardiology Use: The use of oral Timolol in cardiology is expected to continue its slow decline as physicians increasingly opt for newer agents with improved cardiovascular benefits and side-effect profiles.
• Innovation in Delivery Systems: While Timolol itself is an old molecule, innovation may occur in its delivery. The development of more advanced ophthalmic delivery systems (e.g., sustained-release implants, novel topical formulations) could extend its utility and improve patient adherence, but these innovations are more likely to be driven by specialty pharmaceutical companies rather than generic manufacturers.
• Impact of Biosimil/Generic Competition: The market will continue to be saturated with generic versions, leading to sustained price pressure. Any new entrants or significant improvements in manufacturing efficiency by existing players could further impact pricing dynamics.
• Potential for Repurposing (Limited): While unlikely to drive significant market growth, academic research might occasionally explore Timolol for very specific, niche applications where its pharmacological properties could be beneficial. However, this is not expected to represent a substantial market opportunity.

Key Challenges:

• Price Erosion: Intense generic competition will continue to suppress revenue growth.
• Competition from Novel Therapies: Next-generation glaucoma treatments and advanced cardiovascular medications offer superior efficacy or tolerability, gradually shifting prescribing habits.
• Limited Pipeline for New Indications: As an established drug, Timolol has a limited pipeline for developing new therapeutic uses.

Key Opportunities:

• Emerging Markets: In developing economies where cost is a significant consideration, Timolol will remain a critical treatment option for glaucoma.
• Fixed-Combination Products: Continued development and marketing of fixed-combination eye drops containing Timolol can maintain its presence within popular treatment regimens.
• Advancements in Ophthalmic Delivery: Innovations in how Timolol is delivered to the eye could enhance its value proposition by improving patient compliance and potentially reducing systemic absorption.

Key Takeaways

Timolol is a mature drug with a stable, albeit low-growth, market position, primarily driven by its role in ophthalmic treatments for glaucoma. Its cost-effectiveness and established safety profile ensure its continued use, particularly in generic formulations. While significant new therapeutic breakthroughs are not anticipated, innovation in ophthalmic delivery systems could offer incremental advancements. The cardiology market for Timolol is expected to continue its decline.

Frequently Asked Questions

What are the primary therapeutic indications for Timolol currently?

Timolol is primarily indicated for the treatment of open-angle glaucoma and ocular hypertension. Historically, it was also used for cardiovascular conditions such as hypertension and angina, but its use in these areas has significantly decreased.

How does Timolol compare to newer glaucoma treatments in terms of efficacy?

In terms of lowering intraocular pressure (IOP), Timolol is generally effective and comparable to many other first-line agents. However, newer drug classes, such as prostaglandin analogs, may offer different efficacy profiles or fewer systemic side effects for some patients. Combination therapies, including those with Timolol, are often used to achieve target IOPs.

What is the typical pricing strategy for generic Timolol products?

Generic Timolol products are typically priced to be highly competitive, reflecting the intense market competition. Pricing is volume-driven and aims to capture market share by offering a cost-effective alternative to brand-name drugs or more expensive novel therapies.

Are there any significant ongoing clinical trials for Timolol in non-ophthalmic indications?

Significant clinical trials exploring novel non-ophthalmic indications for Timolol are rare. The drug's established profile means that its use in cardiology and other areas is largely based on established therapeutic guidelines rather than active drug development for new uses. Any new research is more likely to be academic or focused on specific subpopulations.

What is the projected market growth rate for Timolol over the next five years?

Given its generic status and the maturity of its indications, Timolol's overall market growth is projected to be low, likely in the low single digits annually. Growth in the ophthalmology segment will be offset by the continued decline in cardiovascular use.

---

Cited Sources

[1] ClinicalTrials.gov. (n.d.). Timolol. Retrieved from https://clinicaltrials.gov/

[2] European Union Clinical Trials Register. (n.d.). Search results for Timolol. Retrieved from https://www.clinicaltrialsregister.eu/

[3] Global Market Insights. (Year). Glaucoma Market Size, Share & Trends Analysis Report. (Specific report details would be included if available and cited).

[4] Grand View Research. (Year). Cardiovascular Drugs Market Size, Share & Trends Analysis Report. (Specific report details would be included if available and cited).